Electrocore (ECOR) Receives New Coverage from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Electrocore (NASDAQ:ECOR) in a report released on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating on the stock.

Other analysts have also issued reports about the stock. JMP Securities began coverage on shares of Electrocore in a research note on Tuesday, July 17th. They set an outperform rating and a $23.00 target price for the company. BTIG Research began coverage on shares of Electrocore in a research note on Tuesday, July 17th. They set a buy rating and a $20.00 target price for the company.

ECOR stock opened at $13.80 on Friday. Electrocore has a twelve month low of $12.85 and a twelve month high of $20.25.

Electrocore (NASDAQ:ECOR) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.17. The firm had revenue of $0.39 million for the quarter.

In related news, Director Carrie Smith Cox bought 3,700 shares of the stock in a transaction dated Friday, August 17th. The stock was purchased at an average cost of $13.76 per share, with a total value of $50,912.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Several institutional investors and hedge funds have recently modified their holdings of ECOR. RTW Investments LP purchased a new stake in shares of Electrocore during the second quarter valued at $8,338,000. Orbimed Advisors LLC purchased a new stake in shares of Electrocore during the second quarter valued at $6,568,000. Sio Capital Management LLC purchased a new stake in shares of Electrocore during the second quarter valued at $3,523,000. Millennium Management LLC purchased a new stake in shares of Electrocore during the second quarter valued at $724,000. Finally, Dean Capital Investments Management LLC purchased a new stake in shares of Electrocore during the second quarter valued at $499,000. 14.98% of the stock is owned by hedge funds and other institutional investors.

Electrocore Company Profile

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Recommended Story: How Buying a Call Option Works

Receive News & Ratings for Electrocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electrocore and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply